The Friends Research Institute Hub is conducting a comparative effectiveness trial of extended-release naltrexone (XR-NTX) versus a new extended-release formulation of buprenorphine (Brixadi, XR-B) to treat OUD among justice-involved individuals in ten Maryland county jails. Participants will be randomly assigned to receive either XR-NTX or XR-B prior to release from jail, followed by six monthly injections while in the community. The goal of the study is to evaluate the effectiveness of the two medications, measure medication adherence, and gather data to inform broader scale-up of MOUD in jails and in the community.
DPA, Friends Research Institute
Shannon Gwin Mitchell
PhD, Friends Research Institute
Health Agency Partner
- Daniel Jarvis, Behavioral Health System Baltimore, Inc.
Justice Agency Partner
- Martha Danner, Frostburg State University